OPTATIO

OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma

 Coordinatore MEDIZINISCHE UNIVERSITAET INNSBRUCK 

 Organization address address: Christoph-Probst Platz 1
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Dr.
Nome: Wolfgang
Cognome: Willenbacher
Email: send email
Telefono: 4351250000000
Fax: 4351250000000

 Nazionalità Coordinatore Austria [AT]
 Sito del progetto http://www.optatio.eu
 Totale costo 4˙284˙452 €
 EC contributo 2˙999˙529 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2011-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-01-01   -   2015-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAET INNSBRUCK

 Organization address address: Christoph-Probst Platz 1
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Dr.
Nome: Wolfgang
Cognome: Willenbacher
Email: send email
Telefono: 4351250000000
Fax: 4351250000000

AT (INNSBRUCK) coordinator 510˙700.00
2    KTB TUMORFORSCHUNGSGESELLSCHAFT MBH

 Organization address address: BREISACHER STRASSE 117
city: FREIBURG
postcode: 79106

contact info
Titolo: Dr.
Nome: Michael
Cognome: Kubbutat
Email: send email
Telefono: +49 761 2061600

DE (FREIBURG) participant 319˙792.50
3    ONCOTYROL-CENTER FOR PERSONALIZED CANCER MEDICINE GMBH

 Organization address address: KARL KAPFERER STRASSE 5/3
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Prof.
Nome: Lukas A.
Cognome: Huber
Email: send email
Telefono: 43512900000000

AT (INNSBRUCK) participant 293˙040.00
4    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

 Organization address address: JOSEF-SCHNEIDER-STRASSE 2
city: WUERZBURG
postcode: 97080

contact info
Titolo: Ms.
Nome: Melanie
Cognome: Bauer
Email: send email
Telefono: +49 931 201 55058
Fax: +49 931 201 61768

DE (WUERZBURG) participant 287˙956.80
5    Masarykova univerzita

 Organization address address: Zerotinovo namesti 9
city: BRNO STRED
postcode: 60177

contact info
Titolo: Dr.
Nome: Sabina
Cognome: Sevcikova
Email: send email
Telefono: +420 54949 3380
Fax: +420 549 498 480

CZ (BRNO STRED) participant 279˙600.00
6    UNIVERSITA DEGLI STUDI DI BARI ALDO MORO

 Organization address address: Piazza Umberto I 1
city: BARI
postcode: 70121

contact info
Titolo: Prof.
Nome: Domenico
Cognome: Ribatti
Email: send email
Telefono: 390805000000
Fax: 390805000000

IT (BARI) participant 262˙800.00
7    "PHARMAMAR, S.A.U."

 Organization address address: "Avda. de los Reyes , Poligono Industrial La Mina 1"
city: COLMENAR VIEJO (MADRID)
postcode: 28770

contact info
Titolo: Ms.
Nome: Elena
Cognome: Calleja
Email: send email
Telefono: +34 918466000
Fax: +34 918234505

ES (COLMENAR VIEJO (MADRID)) participant 239˙880.00
8    VICHEM CHEMIE KUTATO KFT

 Organization address address: HERMANN OTTO UTCA 15
city: BUDAPEST
postcode: 1022

contact info
Titolo: Mr.
Nome: Zoltán
Cognome: Dobai
Email: send email
Telefono: +36 1 4872080
Fax: +36 1 7999990

HU (BUDAPEST) participant 239˙760.00
9    CENTER OF EXCELLENCE IN MEDICINE AND IT GMBH

 Organization address address: KARL KAPFERER STRASSE 5
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Ms.
Nome: Manuela
Cognome: Bock Bartl
Email: send email
Telefono: 43512576523

AT (INNSBRUCK) participant 194˙000.00
10    VEREIN ZUR FOERDERUNG DER KREBSFORSCHUNG IN TIROL

 Organization address address: INNRAIN 66
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Prof.
Nome: Richard
Cognome: Greil
Email: send email
Telefono: +43 66244822879
Fax: +43 66244822898

AT (INNSBRUCK) participant 190˙800.00
11    FOVAROSI ONKORMANYZAT EGYESITETT SZENT ISTVAN ES SZENT LASZLO KORHAZ-RENDELOINTEZET

 Organization address address: NAGYVARAD TER 1
city: BUDAPEST
postcode: 1097

contact info
Titolo: Dr.
Nome: Tamás
Cognome: Masszi
Email: send email
Telefono: +36 1 455 8218

HU (BUDAPEST) participant 144˙000.00
12    THE BINDING SITE GMBH

 Organization address address: ROBERT BOSCH STRASSE 2A
city: SCHWETZINGEN
postcode: 68723

contact info
Titolo: Dr.
Nome: Silvia
Cognome: Kirchner
Email: send email
Telefono: +49 6202 9262 160

DE (SCHWETZINGEN) participant 37˙200.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

supportive    personalised    mm    disease    incurable    screening    refractory    models    drug    validated    pharmaceutical    model    involves    diagnostics    therapies    cells    autologous    myeloma    bone    microenvironment    cell    components    tumour    pathogenesis    interactions    vivo    libraries    multiple    marrow    functionally    culture    optatio    co    vitro    immune    preclinical    subsequently    bmm    assays    resistance    genetic    industry    compounds    clinical    therapy    emergence    data   

 Obiettivo del progetto (Objective)

'Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenvironment (BMM). To target the essential components of this support system, it is the goal of the project to establish preclinical in vitro and in vivo models of MM that include functionally relevant elements of the BMM. The OPTATIO consortium will therefore analyse clinical data to correlate the presence of particular MM-BMM interactions with the pathogenesis of MM, with its intrinsic therapy resistance as well as with disease relapse due to the development of acquired drug resistance. These correlative data will be validated using autologous MM-BMM co-culture assays and reverse translated into in vitro screening and in vivo models, which will be subsequently used to develop lead compounds that target myeloma cells within their microenvironment. The clinical expertise of several oncological divisions, the research experience of academic laboratories and the pharmaceutical know-how of small and medium sized enterprises as well as biotech industry joined their efforts within the OPTATIO consortium to drive this important development and to ensure translation towards clinical trials. Expected impacts of the project include establishment of better diagnostics, new drug screening approaches for MM and novel personalised therapies based on individual ex vivo phenotyping leading to reduced patient mortality. Since envisaged drug screening methods are applicable to other areas of research and development, the project results will open new markets for industry partners in the fields of drug discovery and pharmaceutical development of products and services for personalized medicine.'

Descrizione progetto (Article)

Two thirds of MM cases develop in older patients and they are nearly always incurable. It is a tumour of the immune system that develops from mature antibody-producing B cells.

MM cells grow in niches in the bone marrow. They are surrounded by tissue cells, bone marrow cells, blood vessel cells and immune cells. The BMM helps cancer cells to avoid cell death, thereby making them refractory to medication.

The MM pathogenesis involves not only genetic changes within the tumour but also the emergence of supportive conditions by the BMM. The goal of the EU-funded 'Optimizing targets and therapeutics in high risk and refractory multiple myeloma' (http://www.optatio.eu/ (OPTATIO)) consortium is to target the essential components of this support system.

In the project preclinical in vitro and in vivo models of MM are developed that include functionally relevant elements of the BMM. Clinical data analysis correlates the presence of particular MM-BMM interactions with the pathogenesis and therapy resistance of MM. These data are validated using autologous MM-BMM co-culture assays. In vitro drug screening and in vivo models will be subsequently used to develop lead compounds that target myeloma cells within their microenvironment.

Initially, the consortium created a bank of more than 3000 tumour samples with the database for efficient distribution. Inclusion of BMM into co-culture models was achieved by improvement of 2D co-culture technique and multi-cell type 3D spheroid assays.

Researchers carried out several stages of screening for anti-MM compounds. It included compounds as well as natural product libraries. Compound library screening identified 20 lead candidates. Analysis of marine extract libraries is currently underway.

The consortium developed a murine MM model for the final stage of the in vivo screening. Another developed model employs primary MM cells in mice with a humanised haematopoiesis. This would allow transfer of MM cells autologous to the engrafted human stem cells to study MM-BMM interactions.

Information about OPTATIO progress is regularly disseminated at scientific meetings. Experimental results were presented so far in 15 publications. Expected impact of the project includes better diagnostics, new drug screening approaches and effective personalised therapies for MM treatment.

Altri progetti dello stesso programma (FP7-HEALTH)

EUROCONDOR (2012)

European Consortium for the Early Treatment of Diabetic Retinopathy

Read More  

BIOMAGSCAR (2012)

Biodegradable Magnetic Stent for Coronary Artery Luminal Regeneration

Read More  

SHELTER (2009)

Services and Health for Elderly in Long TERm care

Read More